Voices
Ajay Major: Short Ramp-Up Glofitamab Shows Strong Promise Post-CAR-T in LBCL
Ajay Major/LinkedIn

Ajay Major: Short Ramp-Up Glofitamab Shows Strong Promise Post-CAR-T in LBCL

Ajay Major, Founder and President of Pager Publications and Assistant Professor of Medicine at the University of Colorado School of Medicine, shared a post on X:

“Short ramp-up glofi after LBCL CAR-T
  • 46 pts, short ramp-up to 30 mg by day 8
  • mPFS 3.8 mos, 2-yr PFS 29%
  • mOS 17.3 mos; 2-yr OS 38%
  • mDOCR NR
  • external control comparison: weighted mOS 19.6 vs 7.6 mos (non-BsAb salvage), HR 0.49.

Not randomized, but good support for rapid glofi SUD in post-CAR setting.”

 

Title: Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-specified external control arm

Authors: Guillaume Cartron, Isabelle Chaillol, Roch Houot, Yassine Al Tabaa, Fabien Le Bras, Loïc Ysebaert, Sylvain Choquet, Fabrice Jardin, Jacques-Olivier Bay, François-Xavier Gros, Franck Morschhauser, Cédric Rossi, Thomas Gastinne, Catherine Thieblemont, Magalie Joris, Laure Ricard, Caroline Regny, Laurianne Drieu La Rochelle, Pierre Feugier, Ambroise Marcais, Romain Ould-Ammar, Karin Tarte, Camille Laurent, Pierre Sesques

Read the Full Article.

Ajay Major: Short Ramp-Up Glofitamab Shows Strong Promise Post-CAR-T in LBCL

Other articles about lymphoma on OncoDaily.

Ajay Major Ambroise Marcais Camille Laurent cancer Caroline Regny Catherine Thieblemont Cédric Rossi Fabien Le Bras Fabrice Jardin Franck Morschhauser François-Xavier Gros Guillaume Cartron Isabelle Chaillol Jacques-Olivier Bay Karin Tarte Large B-Cell Lymphoma Laure Ricard Laurianne Drieu La Rochelle LBCL Loïc Ysebaert Magalie Joris OncoDaily Oncology Pierre Feugier Pierre Sesques Roch Houot Romain Ould-Ammar Sylvain Choquet Thomas Gastinne Yassine Al Tabaa